

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/774,887	02/09/2004	Angel Lopez	A20-017DIV	8791	
28156 75	590 05/02/2006		EXAMINER		
COLEMAN SUDOL SAPONE, P.C.			MERTZ, PREMA MARIA		
714 COLORADO AVENUE BRIDGE PORT, CT 06605-1601			ART UNIT	PAPER NUMBER	
	,		1646		
			DATE MAILED: 05/02/200	DATE MAILED: 05/02/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/774,887	LOPEZ ET AL.
Office Action Summary	Examiner	Art Unit
·	Prema M. Mertz	1646
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim 17 rill apply and will expire SIX (6) MONTHS from 18 cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		·
Responsive to communication(s) filed on This action is FINAL . 2b)⊠ This Since this application is in condition for allowan closed in accordance with the practice under E.	action is non-final. ace except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 32-39 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 32-39 are subject to restriction and/or	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce	epted or b) \square objected to by the E	
Applicant may not request that any objection to the dependent drawing sheet(s) including the correction and the correction is objected to by the Example 11).	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Application ty documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	(PTO-413) te atent Application (PTO-152)

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05)

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group 1. Claims 32-33, 36-37, are drawn to a method of inhibiting the IL-5, IL-3 or

GM-CSF mediated leukemic cell proliferation by contacting the leukemia cells in vitro with

monoclonal antibody, classified in Class 435, subclass 7.24.

Group 2. Claims 34-35, 38-39, are drawn to a method of inhibiting 1L-5, 1L-3 or

GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, by

contacting the eosinophils in vitro with monoclonal antibody, classified in Class 424, subclass

7.24.

Group 3. Claims 32-33, 36-37, are drawn to a method of inhibiting the IL-5, IL-3 or

GM-CSF mediated leukemia cell proliferation by contacting the leukemia cells in vivo with

monoclonal antibody, classified in Class 424, subclass 141.1.

Group 4. Claims 34-35, 38-39, are drawn to a method of inhibiting 1L-5, 1L-3 or

GM-CSF mediated eosin Phil activation, eosinophil production or eosinophil survival, by

contacting the eosinophils in vivo with monoclonal antibody, classified in Class 424, subclass

141.1.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in

M.P.E.P. 806.05 for inventive groups that are directed to different methods, restriction is deemed

to be proper because these methods appear to constitute patentably distinct inventions for the

following reasons:

Art Unit: 1646

Inventions 1-4 are independent and distinct, each from the other, because the methods are practiced with materially different process steps for materially different purposes and each method requires a non-coextensive search because of different starting materials, process steps and goals. Therefore, a search and examination of all four methods in one patent application would result in an undue burden.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867.

Application/Control Number: 10/774,887

Art Unit: 1646

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D., J.D. Primary Examiner Art Unit 1646 April 17, 2006 Page 4